SOURCE: Trigen

May 01, 2007 02:01 ET

Trigen's Innovative Platelet Adhesion Inhibitor, PR-15, Successfully Completes First-in-Man Phase I Study

LONDON and MUNICH, GERMANY -- (MARKET WIRE) -- May 1, 2007 --



   - Data to be presented at the XXI Congress of the International
               Society of Thrombosis and Haemostasis -
Munich, Germany, and London, UK, 1 May 2007 - Trigen, the cardiovascular drug discovery and development company, today announced the successful completion of its first-in-man Phase I study of PR-15, the company's innovative platelet adhesion inhibitor.

Dr Sophie Combe, VP Clinical Development at Trigen commented "Based on the promising results of this first-in-man study, investigation of PR-15 in patients is warranted to further evaluate its safety profile and potential efficacy in the management of arterial thrombosis. These results validate the interest expressed by a number of parties in the PR-15 programme and in GPVI as an attractive target for intervention."

The action of PR-15 has been likened to that of a 'vascular sticking plaster' due to its ability to prevent firm platelet adhesion to sites of arterial wall damage including ruptured atherosclerotic plaques. Such adhesion is the first step in platelet activation and aggregation leading to myocardial infarction (heart attack) and stroke and potentially stimulating further progression of atherosclerosis. PR-15 is being developed as a novel agent to treat acute arterial thrombosis and prevent or retard progression of atherosclerosis.

Dr Sanjay Kakkar, CEO at Trigen added, "These results are encouraging and confirm our belief that this innovative candidate drug may offer significant benefit to patients and prescribers. PR 15 is a potentially superior alternative to current acute anti-platelet agents as well as offering an important new option in the fight against restenosis and atherosclerosis."

About Trigen

Trigen is a biopharmaceutical company, with operations in London and Munich and a leader in cardiovascular drug discovery and development, focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical-stage candidates flovagatran, in late-stage clinical development, and PR-15. The company also has an exciting portfolio of pre-clinical and discovery stage programmes targeting thrombosis, atherosclerosis and other cardiovascular pathologies. In addition, Trigen benefits from two established discovery platforms, SIGSCREEN® and THROMSCAN® which have been applied in collaborations with a number of multinational pharmaceutical companies. For further information on Trigen please refer to the company website at http://www.trigen.co.uk or http://www.trigen.de

Contact Details:

Ashley Tapp
Head of Corporate Communications
Trigen
Tel: +44 (0)20 7351 8391
Mob: +44 (0)7944 570387
Email: atapp@trigen.co.uk

Mary Clark/Halina Kukula
Capital MS&L
Tel: +44 (0)20 7307 5330
Email: mary.clark@capitalmsl.com
halina.kukula@capitalmsl.com
- ends -





Copyright © Hugin ASA 2007. All rights reserved.

Contact Information